Patients with wounds bear significant clinical, personal, and economic burdens yet complete wound healing is the only United States Food and Drug Administration (FDA) recognized primary clinical trial end point. The overall goal of this project is to work with FDA to expand the list of acceptable primary end points, recognizing that new and innovative treatments, devices, and drugs may not have complete healing as the focus. Part 1 of the project surveyed 628 wound care experts who identified and content-validated 15 end points most relevant to clinical practice and benefitting patients' lives as primary outcomes in clinical trials. Part 2 is focused on critical appraisal of the evidence in the wound care literature supporting FDA criteria to qualify these 15 end points as primary end points in clinical trials. Further research involved systematic review of the literature regarding the most promising end points. Forty volunteer, interdisciplinary, wound healing experts in fields related to the end points compiled evidence from systematic MEDLINE searches and society databases supporting the FDA criteria of reliability, clinical construct validity, capacity to detect concurrent or longitudinal change, and responder analysis. The search revealed 485 references involving over 462,000 subjects supporting FDA-required parameters for all 15 end points More than 50 references supported FDA-required parameters qualifying the following outcomes for use in clinical trials supporting interventions for FDA clearance: Pain reduction, Physical function and ambulation, Infection reduction, Time to heal, and Percent wound area reduction in 4-8 weeks. Among these, only Time to heal is currently recognized by the FDA as a primary wound outcome in clinical trials. These results suggest that wound science is already serving patients and professionals by improving these content-validated outcomes that merit regulatory consideration.
of moisture-retentive dressings or certain antimicrobial interventions. But, and most importantly, these and many other products were never designed to completely heal wounds.
Appreciation of factors related to the general medical and local conditions of the patient is necessary when determining a treatment plan and/or evaluating the results of a therapeutic intervention. Another facet is that in treating chronic wounds, the immediate goal for clinicians and patients may be to initiate healing, while palliative wound care emphasizes symptomatic care to improve patient comfort. 5, 6 In most instances, it is unlikely that a single product will be useful from wound presentation to closure. Consequently, using drugs, devices, biologics, or interventions to address specific goals of care requires more tailored end points than are currently available.
The FDA lists the following steps required for approving new patient-focused clinical outcome assessments (COAs). 7 The first step Understanding the Disease or Condition, was accomplished by convening wound experts who reviewed the natural history of wounds from onset through diagnosis, pathophysiology, and manifestations for major patient subpopulations in, elaborating patient and caregiver perspectives, treatment options, risks, and benefits across settings. The second step engaged the same wound experts in Conceptualizing Treatment Benefits by identifying measurable outcome concepts of interest, defining their context of use in clinical trials and selecting COAs (the FDA's name for wound end points) that were patient-reported, observer reported or clinician-reported or performance outcomes.
Step three, Selecting/Developing the Outcomes Measures was performed by Wound-care Experts/FDA-Clinical End points Project (WEF-CEP) experts and staff who listed 28 existing wound clinical outcomes from published literature, then began documenting content validity of all 28 clinical outcomes measures through a large online survey of the wound care community, 4 conducted by the WEF-CEP. The purpose of WEF-CEP is to provide meaningful data and interpretation of end points to help the FDA Inter-Center Wound Healing Working Group identify expanded primary outcome end points for inclusion in an updated version of the 2006 Guidance for Industry: Chronic Cutaneous Ulcer and Burn Wounds-Developing Products for Treatment.
The purpose of this phase of the WEF-CEP initiative was to identify and summarize clinical evidence in the wound care literature supporting reliability, content validity, construct validity and capacity to detect concurrent and longitudinal change or using responder analysis (described in Table 1 [8] [9] [10] ) for the 15 WEF-CEP end points rated most relevant for clinical practice and/or patient benefit (Box 1). This was designed to meet the next requirement in FDA Step three of qualifying each end point as a primary clinical trial outcome. To meet this goal, structured literature searches were conducted for evidence supporting each outcome's (1) reliability in stable patients, (2) content validity, (3) construct validity, (4) capacity to detect significant concurrent or longitudinal change, or (5) identify significant effects using responder analysis (see Table 1 for descriptions and examples).
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METHODS
Definitions of research terms
For the purposes of this study, the definitions employed were consistent with FDA criteria for accepting a wound care outcome used to measure effects of a new agent for human use (Table 1) . 7 Systematic literature review of the evidence supporting the 15 key end points Forty-five systematic literature searches were conducted using the MEDLINE database from January 1, 1980 through February 1, 2016. Search terms for each of the end points are listed in Box 1 or their synonyms combined with the terms (1) "valid" or "validity"; (2) "reliable" or "reliability"; and (3) "significant." The latter terms addressed an end point's capacity to detect statistical significance of clinically meaningful longitudinal or concurrent change or responder analyses.
References on the search subject included chronic or acute wounds. Studies were excluded if they were (1) preclinical, (2) lacked clinical evidence, or (3) contained no evidence supporting any of the FDA criteria qualifying the end point for use in clinical trials (Table 1) . Derivative references were included if appropriate. Each reference qualified for inclusion in the count only if it met one or more of the criteria listed in Table 1 (the FDA roadmap criteria) for one of the 15 highly relevant end points.
Forty AAWC and WHS multidisciplinary reviewers were organized into five teams based on their specific wound healing research expertise. They reviewed the literature searches and evaluated references for validity, reliability, ability to detect change, and responder analysis for each major clinical wound type: arterial, diabetic foot, pressure, or venous ulcers; complex ulcers with multiple causes or various wounds studied ensemble; burns; surgical wounds; or traumatic wounds. We did not conduct a systematic review of the identified studies as our goal was to document the abundance of the evidence, to establish that the field is already using these end points as clinical outcomes and publishing articles demonstrating their reliability, construct validity, etc., while using these end points to monitor clinical and patient-centered outcomes.
All searches and references were returned to one author (LLB) to tabulate, analyze, and summarize the results, including number of studies supporting each important wound etiology.
The literature search revealed 4,637 references from which 2,760 were excluded, leaving 1,877 articles that were hand reviewed ( Figure 1 ). Of these, 485 unique references were identified addressing FDA criteria for qualifying end points for use in clinical trials.
RESULTS
These references involving over 462,000 subjects with clinically important wounds were summarized by wound type for each of the 15 end points with robust clinical or patient-centered relevance in Figure 2 . End points with >50 supporting references were Pain reduction, Physical function and ambulation, Infection reduction, Time to heal, and Percent wound area reduction in 4-8 weeks. Acute surgical (full-thickness incisions, excisions, or partial-thickness skin graft donor sites) or traumatic wounds and venous ulcers dominated the evidence supporting some end points. Most evidence on Physical function and ambulation included patients with surgical or traumatic wounds. Evidence on relevant in the clinician survey were: "pain reduction" (mean rating 3.81) "reduction of infection" (3.79), and "increased physical function, ambulation" (3.78) Documented reliability 1. Intrarater reliability: the extent to which a single rater obtains similar ratings on subsequent testing.
1. You repeat a wound visual analogue scale (VAS) 10-cm scale pain measurement at one point in time on the same subject or, set of subjects with a similar result (high correlations between your ratings) 2. You and several colleagues use the same scale to measure pain on the same subject(s) obtaining similar (highly correlated) result(s) Construct validity or criterion-related validity 1. How closely the end point measure agrees with one or more accurate measure(s) of the outcome of interest at a point in time (concurrent validity) or over time (longitudinal validity). 2. The extent of the relationship between instrument measures and a more accurate measure of the phenomenon of interest. 11 1. Your patients rated their own pain on a 10-cm VAS scale and you documented analgesics they were taking at the time. You found their analgesic use strongly correlated with their own pain ratings at that point in time, supporting concurrent validity. For longitudinal validity, these measures would be strongly correlated over time. 2. You find that the number and level of primary amputations in a cohort of patients with diabetic foot ulcers are strongly correlated with higher level amputations and 30-day morbidity/mortality rates. Ability to detect change and responder analysis 1. The ability of the end point to detect changes over time not due to measurement error, i.e., statistically significant differences in the end point for a group of patients over time or between groups over time. Also called Important clinical change or statistical differences One group: You measured immediate postoperative pain using a 10-cm VAS scale, and again using the same scale 7 days later and observed significant reduction (p < 0.05) in patient-reported pain over time. Two or more groups: Using the same measure on two or more groups randomly
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Pain or Analgesic use reduction or Infection reduction was mainly on surgical wounds. Most evidence on Time to heal or Percent wound area reduction from baseline to 4 or 8 weeks focused on venous ulcers. Literature counts supporting each FDA criterion (with associated patients in parentheses) varied across end points and criterion (Table 2 ). Most studies reported multiple FDA criteria for qualification of each end point. These were counted once for each end point represented, causing the numbers of studies in Figure 2 and Table 2 to exceed the total number of references cited.
Overall, most of the evidence found supported either construct validity or ability to detect concurrent or longitudinal change. Healing end points were supported by the most reliability and responder analysis studies. Wound complication, function, and economic end points had more studies supporting construct validity or ability to detect change than reliability or responder analysis. We found no reliability studies supporting Amputation reduction or responder analyses supporting Reduced analgesic use, likely because wound healing studies do not extend out long enough to capture this end point.
Time to heal, due to its recognition as a primary clinical trial end point in the 2006 FDA Guidance document, was among the most studied end point (93 studies; Table 2 ). Even more evidence supported two FDA-qualified secondary end points: Reduced pain (167 studies) and Reduced infection (98 studies), and a third end point not recognized by the 2006 FDA guideline: Improved function and/or ambulation (102 studies). All three of these end points were recognized as useful for both clinical practice and benefitting patients. Economic outcomes Cost effectiveness and/or Cost of treatment (38 and 78 studies, respectively) and Percent area reduction from baseline to 4-8 weeks (54 studies) also had considerable evidence supporting qualification as primary outcomes. These findings suggest that published clinical trials have advanced beyond primary outcomes recognized in the 2006 FDA Guidance to include end points widely recognized 4 as important to informing clinical decisions and/or improving patient-centered outcomes.
DISCUSSION
Systematic searches of peer-reviewed literature found abundant evidence (11-67 studies, each on important wound etiologies) confirming routine use of each of the 15 measurable end points with robust content validated relevance for clinical practice or patient benefits. 4 Timely FDA implementation of these clinically relevant end points as primary outcomes in clinical trials could improve the consistency of professional care and quality of patient outcomes, important to unifying wound care by standardizing end point operational definitions and measurement techniques.
The literature summarized in Table 2 and Figure 2 provided the following insights for consideration in clinical practice and future research:
Time to heal was used as an end point (93 studies/14,646 patients) mainly for detecting clinically important longitudinal or concurrent differences between intervention groups as statistically significant. Clinical observations of complete epithelialization, used to define healing, have been validated against objective digital measures. 12 Most studies (30 studies/5,370 patients) measured this outcome on chronic venous ulcers. assigned to receive different wound dressings, you observe that one group receiving dressing A reported less pain than those receiving dressings B or C 4 days postoperatively, even though their baseline pain levels were similar. Clinical responder analysis In a pain study, patients were initially categorized at the moderate-severe level (5-10 on a 10-point scale). Post intervention they were rated at mild to no pain (0-4). Thus, they changed groups and are defined as responders Percentage area reduction from baseline to 4-8 weeks (54 studies) was used only on patients with chronic wounds (114,228 patients). The literature reviewed included valid, reliable techniques for measuring wound area directly such as image analysis of digital photographs, 13, 14 tracings, or planimetry. 15 Wound area was estimated reliably by weighing wound tracings or by multiplying the longest wound length by its longest perpendicular width. [15] [16] [17] Valid, reliable measures of Percentage area reduction from baseline were calculated from wound area measurements or estimates calculated by: 100 x baseline area -end point area ð Þ = baseline area ð Þ :
This end point was used in the literature both as a measure of healing progress and as a significant predictor of delayed wound healing 12-20 weeks after enrollment. [18] [19] [20] [21] [22] Feedback to care providers about this end point as an early alert to delayed healing improved healing outcomes of venous ulcers or diabetic foot ulcers. 23 Its use has been recommended by the 2006 FDA Guidance document (2) during an early "run in" period, as an early screening tool to identify rapidly healing wounds. Ample research has demonstrated broader potential to inform clinical practice and improve patient outcomes.
Percentage volume reduction from baseline to 4-8 weeks was used as an end point to detect concurrent or longitudinal clinically important change mainly in chronic wounds (11 studies/256 patients) and skin graft donor sites (1 study/288 patients). Wound volume was measured reliably in diabetic foot ulcers except in small or undermined wounds. 24 It was estimated by multiplying the measured or estimated area by wound depth. Percent volume reduction was thus calculated by substituting "volume" for "area" in the formula for percentage area reduction from baseline to 4-8 weeks. Wound depth is a reliable, valid diagnostic measure of wound severity and an independent risk factor predicting delayed healing for diabetic foot ulcers, 25 pressure ulcers, 26 or venous ulcers.
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Reduced recurrence was used as an end point mainly on chronic wounds (21 studies/3,093 patients). The current FDA criterion for Complete wound closure is defined as skin reepithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart. Infection reduction was used as an end point mainly on patients with acute wounds (98 studies/74,232 patients). Considerable research was devoted to developing clear, reliable, valid infection measures which have historically differed across studies, settings, and types of wounds. 27 Surgical site infection definitions proposed by the Centers for Disease Control And Prevention (CDC) and the Nosocomial Infection National Surveillance Scheme version of the CDC standard definition have low diagnostic or screening agreement with each other or with the ASEPSIS quantitative scoring tool. 28 Thus, it can be difficult to tell if a chronic wound is inflamed due to the underlying cause or whether infection per se is the unresolved cause. Reportedly reliable, valid signs and symptoms of chronic wound infection include increasing pain, erythema, edema, heat, purulent exudate, serous exudate, with concurrent inflammation, delayed healing, discoloration of granulation tissue, friable granulation tissue, pocketing at the base of the wound, foul odor, and wound breakdown. 29, 30 The first five of these are valid, reliable symptoms of infection for both chronic and surgical wounds. 31 Research is exploring use of surgical site infection as a performance indicator, based on Medicare claims, 32 highlighting the need for increased clarity. Reduced bioburden was an end point mostly in chronic wound studies (45 studies/58,646 patients). The Levine swab technique has been validated against a clean biopsy for identifying wound organisms, 33 but studies have reported that bacterial cultures are unreliable diagnostic or screening indicators of infection, in particular, isolating millions of colony forming units (CFUs) from wounds without clinical infection signs 27 or not isolating significant CFUs from clinically infected wounds. 27, 34, 35 Clarifying host, environmental and microorganism variable effects on bioburden may improve its reliability and validity as a wound end point. However, it is generally agreed that once validated signs and symptoms identify wound infection, a properly collected swab or biopsy can help identify infecting organisms and their sensitivity to antibiotic agents.
Amputation reduction was used as an end point on chronic or traumatic wounds (22 studies/36,494 patients). Most commonly measured parameters of amputation were major or minor amputation frequency or proximal or distal levels of amputation. 36 Unifying definitions for these end points would allow comparison of outcomes across settings and among interventions. Amputation-free survival is also a common measure of amputation prevention used more specifically for patients with critical limb ischemia and requires a long-term follow-up period, which is rarely seen in wound healing clinical trials.
Pain reduction was used as an end point in studies involving individuals with postsurgical wounds, venous or other types of ulcers, or traumatic injury (165 studies/17,129 patients). A 10-cm visual analog scale (VAS) provided reliable, valid pain measurements, 37, 38 as did the McGill Pain Questionnaire or other quality of life measures quantifying wound pain. 39 Reduced analgesic use typically based on standardized hospital records, was used as an end point, mainly on patients with surgical wounds, burns, or arterial ulcers (42 studies/4,751 patients). This end point has emerging importance that reinforces initiatives to reduce over prescription of opiates associated with addiction. Odor reduction was an end point used mostly with chronic or fungating wounds (27 studies/2,133 patients). Wound odor is one of the classic signs and symptoms of infection and contributes importantly to social isolation. Measures typically used a 10 cm VAS or Likert scale rated by patients or professionals from no odor to mild, moderate, severe, or intolerable.
Reduced social isolation validity and reliability were confirmed for patients with venous ulcers as a dimension of wound-related quality of life measures such as the Nottingham Health Profile 40 or the SF36. 41 Reduced depression was validated as another important quality of life end point for patients with chronic wounds (22 studies/5,491 total; 3,232 chronic wound patients). In addition to studies that measured depression independently, its validity and reliability for use by individuals with wounds have been confirmed as part of the Needs Assessment Checklist 42 and the Hospital Anxiety and Depression Scale. 43 Increased physical function and ambulation was also validated as an end points in patients with acute or chronic wounds (192 studies/69,266 patients) as an important dimension of quality of life in tools like the Nottingham Health Profile 40 or SF-36. 41 Among common measures of function and ambulation are the 6 Minute-Walk Test, 44 postsurgical Walking Speed, 45 or the Timed Get Up and Go Test. 46 These end points are important dimensions in validated scales such as the Spinal Cord Injury Functional Index often used to reflect functional recovery from trauma or surgery. 47 This end point serves doubly as a measure of and a stimulator of recovery, as a patient's number of steps per day predicts faster venous ulcer healing. 48 Cost effectiveness, was a valid outcome for individuals with chronic or acute wounds (38 studies/64,020 patients). It is important to include all aspects of cost supporting the outcome derived. 49 This end point is usually calculated as money spent to derive a patient's outcome or the collective outcomes of a cohort of patients. For ulcer prevention, this end point may be calculated as incremental money spent to achieve each ulcer-free day, week, or month. Relevant references for ulcer prevention or treatment were included in the total cost effectiveness search.
Cost of treatment, often including costs paid by patients with acute or chronic wounds, was the numerator in cost effectiveness end point calculations (78 studies/33,357 patients). Informed payers look past cost of treatment to examine the value received from any wound intervention. Inexpensive, but ineffective treatment can prolong healing or increase complications, resulting in overall increased costs of total wound management. Using a costlier treatment *Each study was counted once for each FDA-required criterion measured, so studies reporting more than one criterion (e.g., reliability, construct validity, etc.) for an end point, were counted more than once, thus inflating numbers.
option with evidence of more rapid healing or reduced complications may actually minimize costs of achieving desired wound outcomes, optimizing cost effectiveness. 50 Our systematic literature review of the evidence may underestimate the research supporting these end points as it includes only references from 1980 to 2016 and only wounds of the etiologies listed in Figure 2 . Studies reporting reliable, valid measures of other wounds, such as those detecting change in function or ambulation following bone fractures without surgical intervention were excluded. Additionally, several end points have been validated, reliability tested, and used to describe significant effects on outcomes related to oncology, rheumatology, or conditions other than those associated with cutaneous wounds. The literature search did not focus on outcomes in palliative care, such as those for malignant, fungating wounds that occur in 5-10% of the more than 14 million individuals worldwide diagnosed annually with cancer. 51 Although healing is rarely an option for cancer patients with malignant fungating wounds, 52 they and their professional and family caregivers rate pain, infection, and odor management, three of the 15 highly rated end points, among their most important challenges in minimizing distress. [53] [54] [55] By focusing on individual end point searches, this literature review likely excluded findings of validation and reliability documentation of end point measures or outcomes already included in validated tools. For example, valid, reliable generic health-related QoL instruments, such as the SF-36 and Nottingham Health Profile include as key elements the high priority end points: Function/ambulation, Reduced social isolation, Reduced depression, and Reduced pain. These outcomes are documented as significant factors influencing QoL for individuals with trauma 56 or burn injuries 57 in literature not returned by searches aimed at the 15 individual high priority end points. The research end points involving pain, function, odor, depression, and social isolation are significant factors contributing to valid, reliable measures of QoL for those with a chronic venous ulcer, 58, 59 neuropathic diabetic foot ulcer, 60 or pressure ulcer. 61 This literature search for evidence supporting FDA qualification of the 15 highly relevant end points as primary clinical end points generally supported the clinicians' estimates of the adequacy of evidence reported in the Phase I Survey of this research project. 4 Respondent ratings of relevance to improving patients' lives reflect only respondents' beliefs that these end points are important to patients. Future research is underway to survey individuals with wounds to identify which of the end points patients believe are relevant to include in clinical trials. This will report content validity of each PL end point's relevance to patients using the same rating scales applied in the original survey.
Implications for future wound care research
Content validation and compiling supporting evidence are important steps toward qualifying these end points as primary clinical outcomes. The 485 studies found in the systematic literature review represent the volume of research supporting reliability, validity, or capability of detecting clinically important differences or response analysis trends for each of the 15 measurable, highly clinically relevant end points. Future researchers will need to close evidence gaps for reliability of Amputation reduction end points or conduct responder analyses for Reduced analgesic use. Research and clinical practice outcomes will be strengthened by developing standardized operational definitions for each end point that is adopted by the wound care community.
Another issue may be tying end points as closely as scientifically possible to phases of wound healing, in which for particular conditions there may be a lack of hemostasis, inflammation, fibroplasia, epithelialization, or maturation. This will support the position that these patients have phased healing and the end points should match clinical reality to choose therapies more wisely and decrease hospitalizations, amputation, and early death.
These proposals would improve the relevance, consistency, and quality of patient-centered outcomes while focusing professionals on the most relevant clinical end points needed to inform wound management decisions. The end result would expand the use of patient centered and clinical end points to include all outcomes listed in Box 1. This would greatly improve relevance, reliability, and validity of clinical care and research trial design as well as encourage development of new medicines and devices that will reduce morbidity and mortality in the wound care patient population.
Further research (Part 3) by the WEF-CEP committee, which has been working on this project for over 3 years, is underway and will expand the survey to include patients, which is intended to (1) address important gap(s), (2) include clinically meaningful end points to patients with wounds, (3) consider patient-centered end points that may have been overlooked, and (4) determine correlation between clinician and patient perspectives.
In conclusion, systematic literature reviews on reliability, clinical construct validity, capacity to detect change, and responder analysis of the 15 previously identified highly relevant wound care end points found considerable evidence supporting FDA criteria for their suitability as primary end points in clinical trials. Some of these end points are already recognized by FDA as secondary clinical trial end points and have sufficient evidence to elevate them to primary end points in regulatory or reimbursement guidance documents. The studies compiled here provide a foundation to build on for those seeking to improve clinical relevance of primary end points used to qualify interventions for safe, effective use, and reimbursement.
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